MedCity News January 17, 2025
AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an initial treatment for this type of blood cancer.
A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma, making it the first in its class approved as a first-line therapy for this rare and aggressive type of blood cancer.
The FDA expanded approval of the drug, acalabrutinib, to include previously untreated MCL in adults who are also ineligible for a hematopoietic stem cell transplant that is a treatment option for younger patients. As a first-line therapy, the AstraZeneca drug must be used in combination with bendamustine and...
Today's Sponsors
Today's Sponsor